Form 4 for ADIL ADIAL PHARMACEUTICALS, INC.
Accepted 2023-05-25 00:00:00 ET · period of report 2023-05-23 · accession 0001213900-23-043111 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-25 | 2023-05-23 | ADIL | Claiborne Cary J | CEO, Dir | A - Grant | $0.00 | +420.0K | 1.52M | +38% | $0 |
| D | 2023-05-25 | 2023-05-23 | ADIL | Claiborne Cary J | CEO, Dir | A - Grant | $0.00 | +300.0K | 300.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-23 | A | A | 420,000 | $0.00 | 1,520,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-05-23 | A | A | 300,000 | $0.00 | 300,000 | D | $0.3 · 2023-05-23 to 2033-05-23 | 300,000 Common Stock | (F1) The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023. |